Abiopharma

🔍 McGraner Matt (Executive)

Company: NEXPOINT DIVERSIFIED REAL ESTATE TRUST (NXDT)

Report Date: 2026-06-10

Detailed Transactions and Holdings:

• Acquired 36,692 shares of Common Stock (Direct)
  Date: 2026-06-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 354,269.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 15,849 shares of Common Stock at $5.07 per share (Direct)
  Date: 2026-06-10 | Code: F | equity_swap_involved: 0 | shares_owned_after: 338,420.00 | transaction_form_type: 4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-10 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 2,127.00 | Footnotes: F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-10 | Code: H | nature_of_ownership: By 401(k) Plan | shares_owned_after: 965.92
• Sold 6,036 shares of Restricted Share Units (Derivative)
  Date: 2026-06-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 110,076.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4

Footnotes:

• F1: Each restricted share unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust (the "Company").
• F2: Includes shares received pursuant to elective stock dividends paid on the Company's common shares.
• F3: The reporting person holds these shares indirectly through a trust for the benefit of certain of the reporting person's family members. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
• F4: On June 10, 2025, the reporting person was granted 146,768 restricted share units. The restricted share units vested one-fourth on June 10, 2026 and will vest one-fourth on February 15, 2027, one-fourth on February 15, 2028 and one-fourth on February 15, 2029. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.
• REMARKS: Executive VP and Chief Investment Officer